Gamco Investors INC. ET AL trimmed its position in Masimo Co. (NASDAQ:MASI – Free Report) by 0.6% in the second quarter, according to its most recent filing with the SEC. The fund owned 84,500 shares of the medical equipment provider’s stock after selling 500 shares during the period. Gamco Investors INC. ET AL’s holdings in Masimo were worth $13,904,000 as of its most recent filing with the SEC.
Other large investors also recently modified their holdings of the company. Financial Gravity Asset Management Inc. bought a new position in shares of Masimo in the 2nd quarter valued at $451,000. National Bank of Canada FI bought a new position in Masimo during the 2nd quarter worth $29,000. Caisse DE Depot ET Placement DU Quebec bought a new position in Masimo during the 1st quarter worth $37,000. Achmea Investment Management B.V. bought a new position in Masimo during the 2nd quarter worth $39,000. Finally, Trivant Custom Portfolio Group LLC bought a new position in Masimo during the 1st quarter worth $55,000. 85.96% of the stock is currently owned by institutional investors.
Masimo Stock Performance
Shares of MASI opened at $94.69 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.14 and a quick ratio of 1.13. The stock has a 50-day moving average of $86.83 and a 200-day moving average of $122.29. The company has a market cap of $5.00 billion, a PE ratio of 57.74 and a beta of 0.88. Masimo Co. has a one year low of $75.22 and a one year high of $198.00.
Wall Street Analysts Forecast Growth
Several research analysts recently issued reports on MASI shares. Raymond James lowered Masimo from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 8th. Needham & Company LLC lowered their target price on Masimo from $136.00 to $86.00 and set a “buy” rating for the company in a research report on Wednesday, November 8th. StockNews.com downgraded Masimo from a “hold” rating to a “sell” rating in a report on Thursday, November 16th. Finally, Wells Fargo & Company decreased their price target on Masimo from $110.00 to $81.00 and set an “equal weight” rating for the company in a report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $122.00.
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and O3 regional oximetry.
- Five stocks we like better than Masimo
- How Can Investors Benefit From After-Hours Trading
- Safeguard your portfolio with these three bargain stocks
- What Are Dividends? Buy the Best Dividend Stocks
- Membership clubs gain leverage for the consumer rebound
- How to Invest in Solar Energy
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.